Caroline Robert, MD, PhD, head, Dermatology Unit, Gustave Roussy, discusses the role of adjuvant anti–PD-1 therapy in the treatment of patients with resected stage IIB/C melanoma, highlighting findings from the phase 3 KEYNOTE-716 (NCT03553836) and CheckMate 76K (NCT04099251) trials that have informed treatment decisions in this setting.
2025
Reprogramming Microglia: A Promising Approach Against Melanoma Brain Metastases
Melanoma, recognized as the most aggressive form of skin cancer, poses significant risks when it metastasizes to the brain.
Metastatic Melanoma Study Finds Immunotherapy Resistance Mutations in Immune-Linked Genes
NEW YORK – A research team led by investigators at the Dana-Farber Cancer Institute and the Broad Institute has uncovered somatic mutations linked to immunotherapy resistance in metastatic melanoma patients who experienced disease recurrence and acquired drug resistance after an initial response to immune checkpoint immunotherapy (ICI).
Dr Hamid on the Potential for Cancer Vaccines in Melanoma
Source: OncLive, February 2025 Omid Hamid, MD, professor, medicine, Cedars-Sinai; director, Clinical Research and Immunotherapy, director, Cutaneous Oncology and Melanoma, The Angeles Clinic and Research Institute, provides insight on the…
Read More